Mabion S.A.
MAB · Warsaw Stock Exchange (GPW) · Healthcare – Biopharmaceuticals
About the company
Mabion is a Polish biopharmaceutical company specialising in the development and manufacture of biosimilar monoclonal antibodies for autoimmune diseases and oncology, and also provides contract development and manufacturing (CDMO) services to international pharmaceutical companies. It is headquartered near Łódź. The company has licensing and supply agreements with international pharmaceutical partners for biosimilar commercialisation.
| Exchange | Warsaw Stock Exchange (GPW) |
| Ticker | MAB |
| Sector | Healthcare – Biopharmaceuticals |
| Indicative market cap USD | $130.00M |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
On its home market (Warsaw Stock Exchange (GPW)), it is accessible through global brokers that offer that exchange:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Warsaw Stock Exchange (Giełda Papierów Wartościowych) — official exchange listing
Availability information only — not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other companies in Poland
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only — not investment advice. Verify with the exchange, the company's filings and your broker.